Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7848854 | 0.85 | HDAC3 (0.57) | SMN1; SMN2ALDH1A1LMNAMAPK1KMT2A | |
| SCHEMBL6802856 | 0.81 | HTR7 (0.58) | SMN1; SMN2ALDH1A1TSHRLMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL6798090 | 0.81 | HTR7 (0.57) | SMN1; SMN2ALDH1A1TSHRLMNAMAPK1 | |
| SCHEMBL7848948 | 0.80 | CCR3 (0.54) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL7848872 | 0.79 | KMT2A (0.49) | SMN1; SMN2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL5577978 | 0.77 | ALDH1A1 (0.58) | ALDH1A1TSHRLMNAKMT2AMEN1 | |
| SCHEMBL10035534 | 0.76 | HTR7 (0.63) | SMN1; SMN2ALDH1A1LMNAMAPK1HTR7 | |
| SCHEMBL7849483 | 0.76 | HDAC3 (0.56) | SMN1; SMN2LMNAKMT2ASLC2A1MEN1 | |
| Hydrochloric Acid SCHEMBL2138390 | 0.75 | HTR7 (0.62) | SMN1; SMN2ALDH1A1LMNAMAPK1HTR7 | |
| SCHEMBL8980468 | 0.75 | HTR7 (0.64) | SMN1; SMN2ALDH1A1LMNAMAPK1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | SMN1; SMN2 4348/4885ALDH1A1 2561/4885TSHR 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.